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against the S1 domain have been generated and all of them 
are able to neutralize the virus in vitro and in vivo using ani-
mal models. Unfortunately, point mutations have been iden-
tified in the S1 domain, so that the virus isolated in the future 
may not be recognized by these antibodies. As no mutation 
has been found in the S2 domain indicating that this region 
is more conserved than the S1 domain, it may be a better 
target for antibody binding. After predicting the immuno-
genicity of the epitopes of the S2 domain, we chemically 
synthesized two peptides and also expressed one of them 
using a recombinant DNA method. We screened a phage dis-
playing library of human single-chain antibodies (ScFv) 
against the predicted epitopes and obtained a human ScFv 
which can recognize the SARS virus in vitro. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Severe acute respiratory syndrome (SARS) is a life-
threatening form of atypical pneumonia caused by a new-
ly identified SARS-associated coronavirus (SARS-CoV) 
 [1, 2] . It apparently began in Guangdong province of Chi-
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 Abstract 
 The outbreak of severe acute respiratory syndrome (SARS), 
caused by a distinct coronavirus, in 2003 greatly threatened 
public health in China, Southeast Asia as well as North Amer-
ica. Over 1,000 patients died of the SARS virus, representing 
10% of infected people. Like other coronaviruses, the SARS 
virus also utilizes a surface glycoprotein, namely the spike 
protein, to infect host cells. The spike protein of SARS virus 
consists of 1,255 amino acid residues and can be divided into 
two sub-domains, S1 and S2. The S1 domain mediates the 
binding of the virus to its receptor angiotensin-converting 
enzyme 2, which is abundantly distributed on the surface of 
human lung cells. The S2 domain mediates membrane fu-
sion between the virus and the host cell. Hence two strate-
gies can be used to block the infection of the SARS virus, 
either by interfering with the binding of the S1 domain to the 
receptor or by blocking the fusion of the virus with the cell 
membrane mediated by the S2 domain. Several antibodies 
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na in November 2002 and spread to several neighboring 
areas, including Hong Kong  [3] . Although the epidemic 
appears to have abated, it is believed that new outbreaks 
of SARS are possible in the future. Since there is no effec-
tive treatment currently available, the development of ef-
fective diagnostics and therapeutics to control the disease 
are of paramount importance  [3] .
 During the last epidemic, SARS patients showed clin-
ical improvement if they were given convalescent serum 
collected from recovered subjects  [4] . However, the source 
of convalescent serum is extremely limited and the sera 
have the possibility of transmitting other blood-borne in-
fections. Although animals can be used to develop anti-
serum against this virus, these sera, being foreign pro-
teins, will elicit immune responses and may cause ana-
phylactic reactions. Thus, it would be ideal to develop 
human antibodies against the SARS-CoV for prophylax-
is or treatment  [5] . This approach of immune therapy has 
been clinically successful when applied in malignant dis-
eases and viral infections  [5–8] .
 There are several ways of developing humanized anti-
bodies. We chose to select antibodies from a phage library 
displaying human single-chain antibodies to facilitate 
the identification and development of specific affinity 
antibodies in a rapid and cost-effective manner. This 
phage library containing millions of independent clones 
of single-chain variable fragment (scFv) antibodies  [9] 
was used to select specific antibodies against the spike 
protein, a major antigenic determinant of SARS-CoV 
 [10] . In order to develop a potent neutralizing high-affin-
ity antibody against SARS-CoV, the spike protein, re-
sponsible for receptor binding and membrane fusion  [10] , 
is targeted for generation of neutralizing   human mono-
clonal antibodies.
 The spike protein of SARS-CoV consists of 1,255 ami-
no acid residues and can be divided into two sub-do-
mains, S1 and S2. The S1 domain mediates the binding of 
the virus to its receptor, angiotensin-converting enzyme 
2, that is richly distributing on the surface of human lung 
cells  [11] . The S2 domain mediates membrane fusion be-
tween the virus and the host cell. Two strategies can be 
employed to block the infection of SARS-CoV, blocking 
either the binding of the S1 domain to the receptor or the 
fusion of the virus mediated by the S2 domain.
 Several humanized antibodies against the S1 domain 
have been generated  [12] and all of these antibodies can 
neutralize the virus in vitro and in vivo. However, point 
mutations have been identified in the S1 domain, so that 
the virus in future outbreaks may not be recognized by 
these antibodies. To our knowledge no mutation has been 
found in the S2 domain. Hence this region is more con-
served than the S1 domain and may be a better target for 
neutralization and antibody production  [10, 13] . After us-
ing a computer program to predict the immunogenicity 
of the S2 domain, peptides were prepared by chemical 
synthesis and recombinant protein expression, and used 
to screen the phage library displaying human scFv anti-
bodies.
 One highly specific scFv, designated A11, was isolated, 
sequenced, expressed and purified. It showed specific re-
activity with SARS-CoV-infected Vero cells in vitro. Al-
though neutralization activity of this antibody is unde-
termined, the high specificity of this antibody to SARS-
CoV makes it useful for diagnosis of SARS-CoV 
infection.
 Materials and Methods 
 Peptide Synthesis and Carrier Protein Conjugation of S2a 
(S783–798) 
 A 16-amino acid peptide designated as S2a from amino acid 
783 to 798 (NFSQILPDPLKPTKRS) and a 26-amino acid peptide 
designated as S2b from amino acid 803 to 828 (LLFNKVT-
LADAGFMKQYGECLGDINA) of the spike protein, a 20-amino 
acid peptide (ERLFLSHPQTKTYFPHFDLH) designated as 
ZETA (irrelevant control) from human   -globin protein were syn-
thesized by the core facility of the University of California at San 
Francisco and were assessed to be  1 95% pure by HPLC. The pep-
tides were conjugated to carrier protein bovine serum albumin 
(BSA; Pierce) or ovalbumin (OVA; Pierce) as described by the 
manufacturer (Imject Immunogen EDC Kit; Pierce) to facilitate 
the panning.
 Expression and Purification of Recombinant S2b (S803–828) 
 The amino acid sequence of the SARS-CoV spike protein was 
used to design a codon-optimized version of the gene encoding the 
spike protein, as described elsewhere  [14] . An oligonucleotide 
based on the DNA sequence encoding amino acids 803–828 (LLF-
NKVTLADAGFMKQYGECLGDINA) of the spike protein was 
synthesized. The sequence of the oligonucleotide is 5  AATTCGC-
TGTTATTTAATAAGGTGACCCTGGCAGACGCGG GG TT CA-
TGAAACAGTATGGTGAATGCTTGGGCGATATTAACGC-
CA-3  . The synthetic gene was cloned into the  Eco RI/ Nco I sites of 
bacterial expression vector pET32b (Novagen) fused with the 3  -
terminal of the thioredoxin (Trx) gene and the sequence was con-
firmed by DNA sequencing. The ligated vector was transformed 
into  Escherichia coli BL21 (Novagen). The S2b Trx fusion protein 
and the Trx control protein from the blank pET32b vector were 
induced to express by isopropyl-b- D -thiogalactopyranoside 
(IPTG) and purified with Ni-nitrilotriacetic acid (Ni-NTA) resin 
(QIAGEN) according to the manufacturer’s protocols.
 Phage Display Library Construction 
 A scFv phage antibody library was constructed in fd phage 
 [15] . The fd phage display library was derived from a phagemid 
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library in pHEN1 vector  [16] by subcloning the  Sfi I/ Not I scFv in-
serts into  Sfi I/ Not I sites of fd vector  [17] . Ligated mixtures were 
used to transform  E. coli TG1 and the transformation mixture 
plated on TYE plates  [16] containing 15   g/ml tetracycline. Li-
brary size was calculated by counting the number of tetracycline-
resistant colonies. Library quality was verified by determining the 
percentage of clones with inserts of appropriate size for an scFv 
gene, performed by colony PCR screening using the primer fdseq 
and fd2  [15] . Library diversity was confirmed by fingerprinting 
the amplified scFv genes after digestion with  Bst NI  [16] . The li-
brary was stored in 2 ! YT medium containing 15   g/ml tetracy-
cline and 15% glycerol at –80°.
 Phage Library Selection 
 Phage-displayed scFvs specific for S2a synthesized spike pep-
tide or recombinant S2b peptide were affinity-selected using pro-
teins absorbed to immunotubes (Nunc, Maxisorb). Immunotubes 
were coated with 10   g/ml of BSA-conjugated S2a or recombinant 
S2b peptide overnight at 4°. The coated immunotubes were 
blocked with 2% (w/v) skimmed milk powder in phosphate-buff-
ered saline (PBS) for 1 h at room temperature. To eliminate non-
specific binding, the phage library was adsorbed in PBS contain-
ing 2% skimmed milk powder. Subsequently, plaque-forming 
units (9  ! 10 11 ) of phage-scFvs prepared from the phage library 
were mixed with blocking buffer and introduced into immuno-
tubes for panning. Unbound phages were removed by 6 washes 
with PBS containing 0.02% Tween 20, followed by 10 washes with 
PBS. Bound phages were eluted with 1 ml of 100 m M triethyl-
amine (Sigma), neutralized with 0.5 ml of 1  M Tris-HCl (pH 7.4) 
and then used to infect 20 ml of exponentially growing  E. coli 
 TG1.  E. coli was grown at 37° for 30 min and then the culture was 
plated on TYE plates containing 15   g/ml tetracycline. After 
overnight growth, colonies were scraped from the plates and used 
to generate phage for a second round of selection as described 
 [15] .
 For the subsequent rounds of panning, selection was alternat-
ed between OVA-conjugated and BSA-conjugated S2a protein to 
prevent selection against the carrier protein. For selection of scFvs 
to the recombinant peptide (S2b) fused with Trx protein, 1 ml of 
10   g/ml recombinant Trx control protein prepared from the 
pET32b blank vector without insert was incubated with the li-
brary for 60 min at room temperature for depletion.
 Phage ELISA 
 Antigen-binding phage antibodies were identified by phage 
ELISA. Individual colonies were picked into 96-well microtiter 
plates containing 2 ! YT with 15   g/ml tetracycline. Bacteria 
were grown overnight at 30°, and then the bacteria were pelleted, 
and the supernatant, containing phage particles, was used for 
ELISA. The spike protein fragments, 10   g/ml of S2a conjugated 
with BSA or OVA or recombinant antigen S2b-Trx, were coated 
onto 96-well plates in 0.1  M sodium bicarbonate solution (pH 9.6) 
overnight at 4°. The next day, the wells were blocked for 1 h at 
room temperature with 2% skimmed milk powder in PBS. 100   l 
of scFv phage supernatant were added to the wells and incubated 
for 1 h at room temperature. The plates were washed and phage 
binding was detected with anti-M13 antibody (Amersham Phar-
macia) as described by the manufacturer. The absorbance was 
read at 405 nm by a plate reader (Molecular Device: Spectra Max 
190).
 DNA Fingerprinting and Sequencing 
 The number of unique phage antibodies was estimated by PCR 
fingerprinting of the scFv genes with the restriction enzyme 
 Bst NI (New England Biolab) and confirmed by DNA sequencing 
 [5] . Sequencing runs were performed in both directions for each 
clone using the fd2 primer 5  -TTTTTGGAGATTTTCAAC-3  
and the fdseq1 primer 5  -GAATTTTCTGTATGAGG-3  .
 Production of Single-Chain Variable Fragment (scFv) 
 The scFv gene fragments were subcloned into pSynI vector 
and transformed into  E. coli BL21 (DE3; Novagen). The scFv ex-
pression was induced by growth in 2 ! YT medium supplemented 
with 100   g/ml ampicillin and 1 m M isopropyl- D -thiogalactoside 
for 4 h at 30°. The scFv was collected from the periplasm. Soluble 
periplasmic extracts were obtained by osmotic shock at 4° using 
lysis buffer containing 20% sucrose, 1 m M EDTA, and 300 m M 
Tris-HCl (pH 8). All the scFvs contain a His-6 tag that allows pu-
rification by Ni-NTA agarose column (Qiagen). The scFvs puri-
fied from the periplasmic extracts were dialyzed with PBS and 
concentrated.
 Western Blot Assay 
 The recombinant S2b protein was prepared with 2 ! SDS load-
ing buffer under reducing conditions (60 m M Tris-HCl, pH 6.8), 
1% SDS, 20 m M dithiothreitol, 10% glycerol, 0.02% bromophenol 
blue). Proteins were separated in 10% PAGE gel and transferred to 
a nitrocellulose membrane. The membranes were blocked in 5% 
nonfat milk in PBS with 0.05% Tween-20 and probed with mouse 
anti-His tagged antibody at a dilution of 1: 10,000 at 4° overnight. 
The membranes were incubated with rabbit anti-mouse horserad-
ish peroxidase-conjugated secondary antibodies (Santa Cruz) at 
a dilution of 1: 4,000 for 2 h at room temperature. The reaction was 
developed with enhanced chemiluminescence reagent (Pierce).
 Immunofluorescence Staining of Vero Cells Infected with 
SARS-CoV 
 BIOCHIPS slides (Euroimmun, Lübeck, Germany), coated 
with SARS-CoV-infected cells and non-infected cells were uti-
lized. 25   l of diluted scFv or SARS patient serum was added to a 
well of the slide and incubated overnight at 4°. The slide was 
washed with PBST (PBS with 0.05% Tween-20), then 20   l of the 
diluted fluorescein-labeled mouse anti-c-myc secondary anti-
bodies (1: 100) was added to the ScFv well and 20   l of the dilut -
 ed fluorescein-labeled goat anti-human secondary antibodies 
(1: 100) was added to the positive control well, and the slide was 
incubated at room temperature for 30 min. The slide was then 
washed with PBST, air dried and mounted. The mounted slide 
was observed under a fluorescence microscope (Leica DML).
 Results (SARS-CoV) 
 Selection and Expression of Spike Protein Fragment 
for Phage Panning 
 Between the two domains the spike protein of the 
CoVs, the S2 domain at the carboxyl end is more con-
served than the S1 subunit  [10, 13] . The amino acid se-
quence of spike protein was analyzed to determine the 
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likelihood that a sequence may trigger an immune re-
sponse in human. Based on the predicted antigenicity, 
hydrophilicity, accessibility, and secondary structures, 
two epitopes, S2a (S783–798) and S2b (S803–828), on the 
S2 domain of spike protein were determined to be anti-
genic and were used to select single-chain antibodies. 
Pure synthetic S2a peptide was conjugated to BSA or 
OVA carrier protein to increase the coating efficiency on 
immunotubes for screening. One problem with this 
method may arise in which antibodies recognizing BSA 
and OVA carrier protein can also be selected. These ir-
relevant bindings can be avoided by alternate use of BSA- 
or OVA-conjugated S2a peptide in selection rounds. For 
phage scFv antibody selection, chemically synthesized 
peptide S2b was tested, but it was found to be very hydro-
phobic and insoluble. S2b was later expressed as a fusion 
protein with Trx in  E. coli  to solve the solubility issue.
 Panning against Purified SARS-CoV Spike Protein 
Fragment 
 A human non-immune phage display antibody library 
was then screened to select the scFv antibodies specific to 
the predicted antigenic determinant region (S2a or S2b) 
of the spike protein. Each round of panning comprised 4 
steps in a cycle of scFv-phage binding to the immobilized 
antigen, washing away of unbound and nonspecifically 
bound scFv-phage, elution of the specifically bound scFv-
phage, and propagation of enriched scFv-phage in bacte-
ria before the output phage scFv goes into the next round 
of panning. The titer of the recovered phage was 7.3  ! 
10 6 and 3.6  ! 10 6 cfu/ml after 4 rounds of selection on 
carrier protein-conjugated S2a and S2b-Trx fusion pro-
tein ( table 1 ). An increase in the number of eluted phages 
after several rounds of panning usually indicates specific 
bindings  [18] .
0
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bait phage eluted
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1st S2a-BSA 1.7!104 S2b-BSA 3.4!104
2nd S2a-OVA 7.8!104 S2b-OVA 8.0!105
3rd S2a-BSA 3.0!105 S2b-BSA 2.8!106
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 Fig. 1. Polyclonal ELISA for S2a ( A ) and S2b ( B ). Polyclonal phages obtained from each round of panning were 
tested for binding to the target antigen and control antigen in ELISA. Binding phages were detected with an 
HRP-conjugated anti-M13 antibody. Positive clones specific to the target were enriched after four rounds of 
selection. 
Table 1. Results obtained after panning
a human phage displaying the scFv 
library (9 ! 1011 cfu diversity) against 
spike protein fragments S2a and S2b
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 To determine the outcome of the selection strategy, 
polyclonal phages were prepared after the 4th round of 
selection and analyzed for their binding to two targets 
fragment (S2a and S2b) by ELISA. After each round of 
panning, the output phage was amplified and applied to 
microtiter wells coated with the respective antigens. Each 
microtiter well was coated with 10   g/ml of the antigen. 
Bound phages were detected by horseradish peroxidase 
(HRP)-conjugated anti-M13 antibody. Phage ELISA 
shows the enrichment of S2a- and S2b-specific phages 
during panning cycles ( fig. 1 ).
 Selection and Identification of scFvs to SARS-CoV 
Spike Protein 
 To identify phages that specifically bind antigens, they 
were prepared from individual colonies from the 4th 
round of selection. The binding specificity of the scFv was 
determined by phage ELISA using the target antigen and 
control proteins as substrates. Forty-eight and 96 individ-
ual clones were picked for the ELISA analysis against S2a 
and S2b spike protein fragments, respectively ( table 2 ).
 Selection on Conjugated Synthetic S2a Spike Protein 
Fragment 
 Of 48 random clones analyzed, 16 clones specifically 
recognized S2a conjugated OVA and BSA proteins, but 
not a control   -globin peptide-conjugated OVA protein, 
OVA or BSA proteins ( fig. 2 ). To determine the number 
of unique antibodies generated, the scFv gene was ampli-
fied by PCR and the PCR product was digested with the 
frequently cutting restriction enzyme  Bst NI (PCR finger-
printing). From the 16 S2a-binding scFvs, the same fin-
gerprint was observed, indicating that they were derived 
from the same phage ( fig. 4 A). DNA sequences of repre-
sentative scFv clones 6 and 13 were identical ( fig. 5 ).
 Selection on Purified Recombinant S2b Spike Protein 
 After four rounds of selection, a total of 96 clones were 
screened for S2b-specific binding by ELISA. Seventy 
clones specifically recognized S2b-Trx protein, but not 
0
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0.7
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n
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S2a-OVA
BSA
S2a-BSA
ZETA-OVA
 Fig. 2. The binding specificity of the se-
lected phage antibodies to S2a. Phages 
were prepared from individual colonies 
from the 4th round of selection and ana-
lyzed for specific binding by ELISA. The 
specificity of anti-S2a scFvs was tested 
against carrier protein (BSA and OVA) 
and carrier protein-conjugated S2a pep-
tide. 
Table 2. Monoclonal ELISA
Target antigen Control antigen Number of ELISA-
positive clones/number 
of antigen-binding 
clones screened
Synthetic S2a Carrier protein (BSA, 
OVA), conjugated 
control peptide
16/48
Recombinant S2b Recombinant vector 
control
70/96
Single clones obtained after 4 rounds of panning were tested for 
binding to the target antigen and control antigen in ELISA. Bind-
ing phages were detected with an HRP-conjugated anti-M13 anti-
body. Signal-to-noise ratios over 2 are regarded as ELISA positive.
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Heavy Chain
2RDC2 krowemarF1RDC1 krowemarF
S2a (C6, 13) QVQLVESGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLEWVS GISGSGGSTYYADSVKG
S2b (A11) QVELVESGGGLVKPGGSLRLSCAASGFTFS AYAMS WVRQAPGKGLEWVS AISGSGGSTYYADSVKG
4krowemarF
4krowemarF
3RDC3 krowemarF
S2a (C6, 13) RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK KQTSSGWYGKDY WGQGTLVTVSS
S2b (A11) RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK GGYCTGGVCSSLDY  RGQGTLVTVSS
Light Chain
2RDC2 krowemarF1RDC1 krowemarF
S2a (C6, 13) SPRQNVGFIVLVPAQGPKQQYWSAYYSRLSDGQCTIRVRQGLAVSVAPDQTLESS
S2b (A11) QSVLTQPPSVSGSPGQSITISC TGTSSDVGAYNFVS WYQQHPGKAPKLMIY DVSNRPS
3RDC3 krowemarF
S2a (C6, 13) GIPDRFSGSSSGNTASLTITGAQAEDEADYYC TSRDRSGNHQ VFGGGTKLTV
S2b (A11) GVSNRFSGSKSGNAASLTISGLQAEDEADYYC SSYTTRSTR VFGGGTKLTV
 Fig. 5. The sequences of the binding phage antibodies. 
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 Fig. 3. The binding specificity of the selected phage antibodies to 
S2b. Phages were prepared from individual colonies from the 4th 
round of selection and analyzed for specific binding by ELISA. 
The specificity of anti-S2b scFvs was tested against carrier protein 
(BSA and OVA), cross-reactivity with conjugated S2a peptide, 
S2b-Trx fusion protein and control protein (Trx). 
 Fig. 4. DNA fingerprint analysis of the scFv genes of individual 
antibodies from the 4th round of selection. scFv DNA was ampli-
fied by PCR directly from colonies and digested with the fre-
quently cutting restriction enzyme BstNI.  A S2a. A unique band-
ing pattern was observed, representing a unique antibody se-
quence.  B S2b. A diverse banding pattern was observed, with each 
unique pattern representing a unique antibody sequence. 
3
4
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A B
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E
 Fig. 6. Immunofluorescence staining of SARS-CoV infected and 
uninfected Vero cells.  A A11-scFv, infected Vero cells.  B A11-scFv, 
uninfected Vero cells.  C Positive control using SARS patient se-
rum, infected Vero cells.  D Negative control using SARS patient 
serum, non-infected Vero cells.  E G10-scFv, infected Vero cells. 
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S2a and vector control protein ( table 2 ). Eight representa-
tive clones showing the highest signals in ELISA were 
identified ( fig. 3 ) and 24 S2b-specific clones were subject-
ed to DNA fingerprint analysis and a diverse pattern was 
observed ( fig. 4 B).  Figure 5 shows the DNA sequencing 
analysis of the clone A11 that has the highest specificity 
and affinity binding to S2b.
 Immunofluorescence Assay on SARS-CoV-Infected 
Cells 
 Four scFvs with higher binding activity (C6, C13, A11 
and G10) tagged with His-6 in pSyn1 vector were ex-
pressed in  E. coli and purified by immobilized metal af-
finity chromatography. Reactivity with SARS-CoV-in-
fected cells by scFvs was assessed by indirect immuno-
fluorescence. This test utilized BIOCHIP containing 
SARS-CoV-infected cells and non-infected cells posi-
tioned side by side in each reaction field. Immunofluo-
rescence analysis revealed that the scFv-A11 specifically 
recognized SARS-CoV infected ( fig. 6 A) but not unin-
fected Vero cells ( fig. 6 B). Although the other 3 ScFvs (C6, 
C13, G10) bound S2b fusion protein on ELISA, they did 
not bind the infected Vero cells. The negative binding of 
G10 is shown in  figure 6 E.
 Specificity of A11 to Recombinant Spike Protein 
 A11 scFvs was demonstrated to show specific binding 
to the spike protein fragment peptide in ELISA assays 
and to SARS-CoV-infected cells. To further confirm the 
interaction between A11 scFv and recombinant spike 
 Fig. 7. Western blot analysis for A11-scFv on recombinant spike 
protein. A11-scFv recognized recombinant spike protein S2-b, but 
did not bind to vector control. 
protein, Western blot was performed. In  figure 7 , A11-
scFV was found to have specific binding to recombinant 
S2b protein, but not to the vector control. Anti-His-tagged 
protein is shown as control.
 Discussion 
 The sequence variation of infectious viruses limits the 
development of effective vaccines or neutralization anti-
bodies against these viruses. Like other coronavirus, the 
SARS virus also uses its S1 domain of the spike protein to 
bind the receptor of the host cells. The best way to block 
the infection of the virus is to block the binding of the 
virus to the receptor. Although neutralization antibody 
against this domain has been developed, most mutations 
of the SARS virus have been found in this region, and 
hence some virus may escape recognition by the neutral-
ization antibody. However, the S2 domain is very well 
conserved among all corona viruses and so far no muta-
tion has been found in the S2 domain of SARS virus. 
Hence this region is a better target than the S1 domain 
for the development of vaccine and neutralization anti-
bodies against the SARS virus. Furthermore, the combi-
nation of different neutralization antibodies against mul-
tiple epitopes may facilitate the clearance of virus from 
human blood.
 The epitope Leu803-Ala828, S2b fragment, was identi-
fied previously as a peptide that had strong binding to 
convalescent sera from SARS patients  [19] . It was also se-
lected as a potential vaccine sequence for SARS virus. 
However, this peptide is hydrophobic and very hard to 
dissolve in water. Hence we synthesized the DNA frag-
ment for this peptide and cloned the DNA fragment into 
the pET32b vector. The peptide was expressed as a soluble 
fusion protein in bacteria, after purification, the recom-
binant peptide was used to screen the human ScFv library 
for SARS antibody.
 We obtained 8 unique clones for S2b recombinant 
peptide after 3 rounds of screening, but only one clone, 
A11 had specific binding activity for SARS virus. Perhaps 
the fusion of the S2b peptide changed the conformation 
of fusion protein and generated new epitopes in the fu-
sion protein. Nevertheless, we were able to obtain one 
clone highly specific to the S2 domain of the spike pro-
tein. Hence this method may be useful for other hydro-
phobic peptide target. The library can be depleted by 
blank recombinant protein without the peptide and the 
recombinant peptide does not need conjugation with car-
rier proteins such as BSA or OVA.
A11-scFv
Anti-His
S2b Vector
 Development of Human Single-Chain 
Antibodies against SARS-CoV 
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 The A11 scFv antibody may have possible therapeutic 
utility for neutralizing SARS-CoV infection. Thus, it is 
worthwhile to further investigate the A11–scFv interac-
tion with native spike protein and to produce the whole 
humanized antibody for viral-neutralizing assays to pro-
vide a more precise assessment on its neutralizing effect 
and the potential for further in vivo and clinical studies.
 In summary, a human scFv antibody A11 directed to 
the spike protein Leu803-Ala828 of SARS-CoV has been 
identified which can bind specifically to SARS-CoV pro-
tein and viral particles. The VH and VL of the A11 anti-
body has been sequenced, thus facilitating molecular ap-
proaches including site direct mutagenesis for affinity 
maturation and construction of a whole recombinant hu-
man antibody for studies of SARS-CoV neutralization.
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